- Published at
- by manilatimes.net
positive
positive
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
**media[588445,588446]**
News for Daewoong pharmaceutical Co.,Ltd. (069620.KS)
- Published at
- by gurufocus.com
mixedmixedEvolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results f- Published at
- by gurufocus.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the g- Published at
- by gurufocus.com
mixedmixedEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance
[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary,- Published at
- by gurufocus.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the g- Published at
- by gurufocus.com
neutralneutralHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
PR NewswireROCKVILLE, Md. and SEOUL, South Korea, Nov. 25, 2024 HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participan- Published at
- by investing.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)- Published at
- by investing.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)- Published at
- by investing.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)- Published at
- by investing.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)- Published at
- by marketscreener.com
mixedmixedEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of...- Published at
- by marketscreener.com
mixedmixedEvolus to Report First Quarter Financial Results on May 7, 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on...- Published at
- by prnewswire.com
neutralneutral- Published at
- by prnewswire.com
positivepositiveDaewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
/PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE:688222.SH) today announced that it has entered into a research collaboration...- Published at
- by prnewswire.com
neutralneutral- Published at
- by prnewswire.com
positivepositiveHanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
/PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) and Daewoong Pharmaceutical (KRX: 069620.KS) today announced expansion of their open collaboration strategy...- Published at
- by seekingalpha.com
mixedmixedEleison Pharmaceuticals: Betting On Late-Stage Candidates For Orphan Diseases (ELSN)
Eleison Pharmaceuticals acquires, develops and commercializes late-stage therapies for orphan diseases with unmet needs. Read our analysis on ELSN here.- Published at
- by prnewswire.com
mixedmixedGlobal Botulinum Toxin Market to Reach $7.9 Billion by 2026
/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...- Published at
- by thestreet.com
mixedmixedGlobal Botulinum Toxin Market To Reach $7.9 Billion By 2026
SAN FRANCISCO, June 29, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today- Published at
- by globalbankingandfinance.com
positivepositiveIncreasing Healthcare Spending Enabling Growth in Antibiotics Active Pharmaceutical Ingredient (API) Market: FMI Report
Increasing expenditure on health care, in addition to increasing demand for generic medicines, is aiding the expansion of antibiotics active pharmaceutical